1 er 16 patients (61+/-8 years, 1 female) were
randomized.
2 gnosed at US were prospectively enrolled and
randomized.
3 ptember 17, 2014, and November 18, 2015, and
randomized 1:1 in a masked fashion to receive bevacizuma
4 ron therapy) patients without cirrhosis were
randomized 1:1 to receive 12 or 16 weeks of G/P (300 mg/
5 Forty patients were
randomized 1:1 to treatment with serelaxin intravenous (
6 METHODS AND In Bangladesh, we cluster-
randomized (
1:1) 142 villages of the Matlab Health and D
7 tinine <1.2 mg/dL, and normoalbuminuria were
randomized (
1:1) with permuted blocks to 6 months of a 2
8 0) enrolled infants born to women previously
randomized (
1:1:1:1) to receive either GBS vaccine at do
9 s (interquartile range, 3.0-8.0 months) were
randomized;
110 children were placed in the EHCF group,
10 METHODS AND We
randomized 12 subjects with heart failure with preserved
11 x, 65.8%) were mite sensitized, and 284 were
randomized (
146 to the active group and 138 to the place
12 The authors
randomized 150 patients with advanced HF between August
13 We
randomized 156 adult subjects undergoing cardiac surgery
14 Randomized 2 x 2 factorial clinical trial in neonates (>
15 is In Myocardial Infarction 54) trial, which
randomized 21,162 patients to ASA alone, ticagrelor 60 m
16 A total of 494 patients were
randomized,
25 did not meet the criteria and 469 were an
17 ected Coronary Artery Disease) prospectively
randomized 350 patients with stable angina (55% women; a
18 We
randomized 54 stable outpatients with cirrhosis and asci
19 ed in the third protocol amendment; 28 sites
randomizing 709 of the 1,006 patients participated.
20 VISTA and VIVID
randomized 872 DME patients to receive intravitreal afli
21 We
randomized 960 participants in 120 peer educator groups
22 Randomized and nonrandomized comparative studies that en
23 Initially, 157
randomized and nonrandomized studies on therapies (syste
24 A total of 267 patients were
randomized,
and the study arms were well matched at base
25 Randomized,
assessor-blinded, single-center study within
26 nse to egg white (EW) of less than 2 mm were
randomized at age 4 months to receive whole-egg powder o
27 METHODS AND We performed a
randomized (
at patient level, blocks of 4), controlled n
28 Out of the five
randomized bases, a 5' thymidine is present in most of t
29 now, qubits have been assessed primarily by
randomized benchmarking, which reports a different error
30 esophageal junction tumors (Siewert I), were
randomized between open and MI esophagectomy with curati
31 Using block randomization, patients were
randomized between oral study medication and CBT (2:1) f
32 BENEFIT was a
randomized clinical trial comparing early versus delayed
33 Randomized clinical trial conducted at 2 urban EDs in th
34 This
randomized clinical trial demonstrated better postoperat
35 -masked, parallel-group, placebo-controlled,
randomized clinical trial included 117 patients with pla
36 loratory analysis of secondary outcomes of a
randomized clinical trial of extremely preterm infants,
37 Four-group cluster
randomized clinical trial of mothers of healthy term new
38 In this 2-year, follow-up,
randomized clinical trial of patients with Duchenne or B
39 itute (NCI) sponsored, multicenter, phase 3,
randomized clinical trial open to patients with biopsy-p
40 xploratory analysis of the multicenter FinXX
randomized clinical trial that accrued 1500 women in Fin
41 A
randomized clinical trial was conducted from February 1
42 A double-blinded, placebo-controlled
randomized clinical trial was conducted from October 1,
43 different breast cancer subtypes in a large,
randomized clinical trial with long-term follow-up.
44 In this
randomized clinical trial, 268 active-duty servicemember
45 In this secondary analysis of a phase 3
randomized clinical trial, a low level of preexisting cy
46 y, including 9 retrospective reports and one
randomized clinical trial, and five retrospective studie
47 This parallel-design, double-blind,
randomized clinical trial, called Resveratrol to Improve
48 In this 2-group, parallel,
randomized clinical trial, including a nonrandomized obs
49 In this substudy of a
randomized clinical trial, study eyes of subjects assign
50 A multicenter phase 2
randomized clinical trial, the Arginine Deiminase and Me
51 t of Acute Cerebral Hemorrhage II (ATACH-II)
randomized clinical trial.
52 English-language
randomized clinical trials (RCTs) or prospective cohort
53 We included
randomized clinical trials and prospective observational
54 kin) may improve vascular diseases; however,
randomized clinical trials are needed to confirm these f
55 The lack of prospective
randomized clinical trials demonstrating that full-body
56 An initial meta-analysis identified 14
randomized clinical trials for treatment of mNSCLC with
57 Randomized clinical trials in which self-guided iCBT was
58 Four
randomized clinical trials met the selection criteria an
59 orts use of PB-MRD as a primary end point in
randomized clinical trials of chemoimmunotherapy in CLL.
60 and BCL6 translocations in two prospectively
randomized clinical trials of patients with diffuse larg
61 tional meta-analysis and create a network of
randomized clinical trials to compare outcomes after spe
62 this area are conflicting, and there are no
randomized clinical trials to guide practitioner decisio
63 ow how Bayesian analysis takes evidence from
randomized clinical trials to update what is already kno
64 Results From 109 included
randomized clinical trials, 108 ASCOv1, 111 ASCOv2, and
65 y reviewed and selected studies if they were
randomized clinical trials, included adults hospitalized
66 we sought systematic reviews, meta-analyses,
randomized clinical trials, prospective comparative obse
67 wering treatment can be established only via
randomized clinical trials.
68 Single site
randomized control trial, 3 groupsx4 time points mixed f
69 richment (biomarker-positive patients) and a
randomized controlled design by pre-approval trials and
70 The
randomized controlled Mycotic Ulcer Treatment Trial (MUT
71 systematic review was conducted to identify
randomized controlled studies comparing nurse-led self-m
72 s in both members of the dyad.We conducted a
randomized controlled study of 97 mother-infant dyads.
73 This
randomized controlled trial examined the efficacy of a n
74 We conducted a
randomized controlled trial of AF screening using an Ali
75 We studied participants from a
randomized controlled trial of primary prevention with s
76 We conducted a prospective
randomized controlled trial to study the impact of in-ho
77 We performed a parallel-arm
randomized controlled trial to test whether administrati
78 ate Cancer: Evaluation of Drug Efficacy is a
randomized controlled trial using a multiarm, multistage
79 ial multiple-assignment randomized trial (or
randomized controlled trial) may be inadequate.
80 In this
randomized controlled trial, 128 young adults (71 male,
81 n (WS) and the risk of weight regain.In this
randomized controlled trial, 61 healthy overweight or ob
82 Quasi-
randomized controlled trial.
83 Prospective, single-center, nonblinded,
randomized controlled trial.
84 While
randomized controlled trials (RCTs) are based on strict
85 hed PubMed, EMBASE, and PsycINFO to identify
randomized controlled trials (RCTs), meta-analyses, and
86 ions retrieved, 42 met inclusion criteria (5
randomized controlled trials and 37 observational studie
87 This study sets the stage for larger
randomized controlled trials and testing in other emotio
88 Randomized controlled trials are required to confirm the
89 Further data from
randomized controlled trials are urgently needed because
90 We searched electronic databases for
randomized controlled trials comparing AL to non-ACTs th
91 literature review and identified more recent
randomized controlled trials comparing dose-escalated ex
92 Two reviewers independently identified
randomized controlled trials comparing dynamic assessmen
93 tion of FA and focuses on recently published
randomized controlled trials exploring the efficacy of o
94 Randomized controlled trials have demonstrated that the
95 INAHL, and CENTRAL through July 1, 2016, for
randomized controlled trials of CCT in older adults with
96 Most
randomized controlled trials of routine versus selective
97 RATIONALE: Single-center
randomized controlled trials of the Zephyr endobronchial
98 Assessing surgery in
randomized controlled trials raises several challenges.
99 Hence, authors and journals publishing
randomized controlled trials should pay attention that s
100 In total, 17
randomized controlled trials were identified, including
101 Twenty-three
randomized controlled trials with 2,751 patients were in
102 Rigorous double-blind, placebo-controlled,
randomized controlled trials, using commonly available o
103 We performed a prospective,
randomized,
controlled trial in nondiabetic DIOS patient
104 This double-blind,
randomized,
controlled trial investigates the effects of
105 In a
randomized,
controlled trial that compared liraglutide,
106 ouraging preliminary results, we conducted a
randomized,
controlled trial to determine whether minocy
107 We present here a
randomized,
controlled trial using allogeneic MSC, which
108 se recommendations on a systematic review of
randomized,
controlled trials and systematic reviews pub
109 from professional societies supplemented by
randomized,
controlled trials; meta-analyses; and system
110 TRANSGRIPE 1-2 is a phase 3,
randomized,
controlled, multicenter, open-label clinical
111 ducted two parallel, pragmatic, multicenter,
randomized,
controlled, open-label trials with blinded o
112 placebo over 2 test days in a double-blind,
randomized,
counterbalanced, cross-over design.
113 A single-blind
randomized crossover design was used.
114 This was a prospective
randomized crossover study in nonintubated patients with
115 In a
randomized double-blind placebo-controlled study, 56 pat
116 Four hundred forty-six CAE children in a
randomized double-blind trial of ethosuximide, lamotrigi
117 label study including 12 patients; a phase 3
randomized,
double blind, placebo controlled study invol
118 he field treatment of actinic keratosis in a
randomized,
double-blind clinical trial involving 131 pa
119 Purpose LUME-Meso is a phase II/III
randomized,
double-blind trial designed to assess effica
120 A
randomized,
double-blind, multisite placebo-controlled t
121 In this
randomized,
double-blind, phase 3 study, we assigned 339
122 (
Randomized,
Double-Blind, Placebo Controlled Study of th
123 In a
randomized,
double-blind, placebo-controlled crossover s
124 omical brain magnetic resonance imaging to a
randomized,
double-blind, placebo-controlled trial (RCT)
125 This
randomized,
double-blind, placebo-controlled trial asses
126 METHODS AND TIME was a
randomized,
double-blind, placebo-controlled trial compa
127 We conducted a phase 2,
randomized,
double-blind, placebo-controlled trial in 27
128 METHOD: This 6-week,
randomized,
double-blind, placebo-controlled trial inclu
129 Antidepressant Sertraline Trial (CAST) was a
randomized,
double-blind, placebo-controlled trial invol
130 We conducted a
randomized,
double-blind, placebo-controlled trial of am
131 In this prospective, multicenter,
randomized,
double-blind, placebo-controlled trial, 96 H
132 We conducted a phase I,
randomized,
double-blind, placebo-controlled, dose-escal
133 This
randomized,
double-blind, placebo-controlled, multicente
134 In this multicenter,
randomized,
double-blind, placebo-controlled, parallel-g
135 rea in an African Region with Malaria) was a
randomized,
double-blinded, placebo-controlled trial con
136 In 2 large,
randomized,
double-masked trials reported here, once-dai
137 Twelve-week, phase III,
randomized,
double-masked, multicenter, placebo-controll
138 id macular edema (PCME) using a prospective,
randomized,
double-masked, placebo-controlled clinical s
139 Thirty-two patients were
randomized equally into 2 treatment arms (control and in
140 ondary analysis of prospective data from the
Randomized Evaluation of Sedation Titration for Respirat
141 lysis of data from the 36-month prospective,
randomized,
FAME A and B trials.
142 Patients were
randomized in a 1:1 fashion and stratified according to
143 acutely medically ill subjects (n=7513) were
randomized in a double-dummy double-blind fashion to eit
144 m 401 patients enrolled in the international
randomized International Extranodal Lymphoma Study Group
145 agmatic, general practitioner-based, cluster-
randomized intervention trial compared the intervention
146 al acuity (VA) assessor-masked, multicenter,
randomized,
interventional study.
147 mplications requiring PPV were prospectively
randomized into 1 of 2 treatment groups: Group A receive
148 Participants were
randomized into 2 incubations arms, either 10-minute or
149 l data from 2092 patients with enteric fever
randomized into 4 trials in Kathmandu, Nepal, were poole
150 genation emergency (Sim1-recirculation) then
randomized into simulation and traditional groups.
151 udy consisting of 1 screening and 2 separate
randomized-
masked ITN treatments (sham extranasal or int
152 Of the 721 patients
randomized (
mean [SD] age, 61.4 [10.5] years; 53.1% male
153 Among the 925 patients who were
randomized (
mean [SD] age, 9.7 [5.3] years; 575 males [6
154 Of 361 children and adolescents who were
randomized (
mean [SD] age, 9.8 [3.2] years; 38% female;
155 ts and continued metformin in the originally
randomized metformin group.
156 This prospective
randomized multicenter trial provides evidence that clin
157 We analyzed individual patient data from 13
randomized multicenter trials of induction and maintenan
158 nce Performance in Dialysis trial, a 6-month
randomized,
multicenter trial to test whether a simple,
159 Prospective,
randomized,
multicenter, controlled clinical trial.
160 This was a prospective,
randomized,
multicenter, single-blinded trial.
161 To pilot a cluster-
randomized,
multiple-crossover trial using software tool
162 This
randomized noncomparative design allowed safety evaluati
163 Double-masked,
randomized noninferiority clinical trials: Rho Kinase El
164 12-week, single-blind, 3-group
randomized noninferiority trial and subsequent 40-week m
165 We performed a blinded,
randomized,
noninferiority trial comparing iodine povacr
166 fined as an HRSD17 of 7 following 8 weeks of
randomized open-label treatment ADMs: escitalopram, sert
167 single-center, parallel-group, prospective,
randomized,
open-label, blinded end point trial, consent
168 ms; control protocol) on separate days in a
randomized order.
169 We performed a
randomized,
parallel, single-blind dose-ranging phase 2
170 Phase 2,
randomized,
parallel-group, dosage-finding, 26-week tria
171 board-approved, single-center, prospective,
randomized,
parallel-group, open-label treatment trial w
172 We conducted a double-blind,
randomized,
parallel-group, placebo-controlled trial of
173 Among the 136
randomized participants (mean age, 50.4 [SD, 13.3] years
174 Among 480
randomized participants, 465 (97%) were included in the
175 Of the 50
randomized participants, 49 (98%) received all 3 lamotri
176 Among 477
randomized patients (mean age, 44 years [SD, 15]; women,
177 Among 336
randomized patients (mean age, 68 years; 16% women), 333
178 Among 401
randomized patients, 2 withdrew immediately after random
179 Of 722
randomized patients, 552 had cytogenetic results; 137 (2
180 Of the 2032
randomized patients, baseline health status was availabl
181 cted a prospective, multicenter, open-label,
randomized phase III trial that compared a busulfan-base
182 Prospective,
randomized,
pilot study.
183 A38 patients, and carried out a double-blind
randomized placebo-controlled study for 16 weeks, follow
184 We thus performed a
randomized placebo-controlled trial with atorvastatin 40
185 Therefore, we conducted a double-blind,
randomized,
placebo-controlled crossover trial in 18 adu
186 In this multicenter, double-blind,
randomized,
placebo-controlled study, 74 participants wi
187 per DSM-IV-TR criteria were enrolled in this
randomized,
placebo-controlled trial consisting of an in
188 In this multicenter, double-blind,
randomized,
placebo-controlled trial, we assessed the ef
189 ame as those found in all four much smaller,
randomized,
placebo-controlled trials specifically desig
190 Using a double-blind,
randomized,
placebo-controlled, parallel design, we test
191 In this double-blind,
randomized,
placebo-controlled, phase 2 trial, we assign
192 We initiated a
randomized,
placebo-controlled, phase 3 trial of the chi
193 omly to the Strong African American Families
randomized prevention trial or to a control condition.
194 In a
randomized prospective trial, the imaging modalities wer
195 Multicenter,
randomized,
prospective, single-masked trial.
196 ondary analysis of data from the prospective
randomized Recompensation of Exacerbated Liver Insuffici
197 Randomized,
single-masked, controlled trial.
198 not reduce 28-day/hospital mortality in the
randomized studies (relative risk, 0.93; 95% CI, 0.77-1.
199 intervention in type 2 diabetes, but further
randomized studies are warranted.
200 tle-Ottawa Scale and the Risk of Bias in Non-
randomized Studies of Interventions tool, respectively.
201 Inclusion criteria were observational or
randomized studies of septic patients, evaluation of ant
202 In total, 32 eligible non-
randomized studies with 4697 patients (LLR: 1809, OLR: 2
203 The ERSPC (European
Randomized Study of Screening for Prostate Cancer) found
204 s, we demonstrate that an approach of local,
randomized tailoring of bond stiffness via microalloying
205 Peer educator-FSW groups were
randomized to 1 of 3 arms: (1) delivery (direct distribu
206 Female smokers
randomized to 21 mg nicotine (TNP; n=37) or placebo (PBO
207 All participants were implanted and
randomized to a paired VNS (n = 16) or control (n = 14)
208 Sixty healthy adult volunteers were
randomized to a single standard, autologous, leukoreduce
209 s board approval, second year residents were
randomized to a teaching intervention targeting cognitiv
210 with HER2-positive metastatic breast cancer
randomized to an antibody-based (trastuzumab) vs a small
211 y-eight communities in Matameye, Niger, were
randomized to annual oral azithromycin treatment of the
212 Thirty pigs were anesthetized and then
randomized to cardiac arrest induced by three diffrent m
213 Patients were
randomized to either an NT-proBNP-guided strategy or usu
214 d an emphysematous appearance, patients were
randomized to either standard management or intervention
215 Patients
randomized to etelcalcetide were significantly more like
216 During year 1, patients were
randomized to evolocumab, 420 mg, plus standard of care
217 rch 8, 2012, to September 23, 2014, and were
randomized to group or individual CPT.
218 Participants were
randomized to one of the following study arms: view a on
219 o thrombus aspiration and 262 of 9151 (2.9%)
randomized to PCI alone (hazard ratio, 0.84; 95% confide
220 Only patients
randomized to placebo were considered.
221 -volume pancreas centers were preoperatively
randomized to placement of a drain or no drain.
222 mary percutaneous coronary intervention were
randomized to prasugrel or ticagrelor with an intended t
223 wing percutaneous coronary intervention were
randomized to ranolazine versus placebo.
224 Eligible children were
randomized to ready-made or custom-made spectacles.
225 ty patients not eligible for adalimumab were
randomized to receive 12 weeks of blind treatment with p
226 Three hundred forty-nine participants were
randomized to receive 2000 IU/d of vitamin D oral supple
227 Healthy, HIV-uninfected adults were
randomized to receive 4 mg of PENNVAX-G DNA delivered in
228 igh-dose group) vs 354 participants who were
randomized to receive 400 IU/d (standard-dose group) for
229 participants 65 years or older with PAD were
randomized to receive a daily capsule of resveratrol, 12
230 Patients were
randomized to receive concurrent pyridoxine (200 mg) or
231 ticipants with allergic rhinitis (n=42) were
randomized to receive eight weekly doses of i.n.
232 agia and active esophageal eosinophilia were
randomized to receive either BOS 2 mg or placebo twice d
233 Adults/adolescents (N = 1071) were
randomized to receive either omalizumab (n = 542) or pla
234 Six healthy adult males were
randomized to receive either single daily 80 mg doses of
235 recruited for this study; 270 patients were
randomized to receive eravacycline, and 271 patients wer
236 receive eravacycline, and 271 patients were
randomized to receive ertapenem.
237 al, 401 participants aged 6 to 11 years were
randomized to receive once-daily tiotropium 5 mug (2 puf
238 rom community groups, 5110 participants were
randomized to receive vitamin D3 (n = 2558) or placebo (
239 Patients were
randomized to robotic-assisted (n = 237) or conventional
240 mcitabine-based chemotherapy had failed were
randomized to selumetinib plus MK-2206 or mFOLFOX.
241 Disease (MDRD) Trial participants previously
randomized to strict versus usual BP control.
242 ge] age, 12.9 [11.2-15.3]), of whom 684 were
randomized to the control group and 685 to the intervent
243 months; 468 [60.2%] male), 385 (49.5%) were
randomized to the HS group and 387 (49.8%) to the NS gro
244 7.8 kg; mean months post partum, 5.2 months)
randomized to the intervention group (n = 174) or standa
245 Patients were
randomized to the liberal (hemoglobin threshold, < 9 g/d
246 A total of 52 patients were
randomized to the rotating arm (median [range] age, 65 [
247 days occurred in 221 of 9155 patients (2.4%)
randomized to thrombus aspiration and 262 of 9151 (2.9%)
248 In a double-blind trial, patients were
randomized to tolvaptan 30 mg/day or placebo.
249 al artery stenotic or occlusive lesions were
randomized to treatment with plain balloon angioplasty (
250 Patients were
randomized to TTM (33 +/- 1 degrees C) for 48 hours (n =
251 Patients
randomized to UC + PAL versus UC alone had clinically si
252 rgoing PM for Stage 0-III breast cancer were
randomized to undergo either standard PM ("no shave", n
253 cebo-controlled trial, 96 HT recipients were
randomized to undergo ramipril or placebo therapy.
254 Participants were
randomized to vitamin E, selenium, vitamin E and seleniu
255 thy male subjects (n=29) participated in two
randomized treatment periods of daily placebo or PF-0495
256 Eighty-five patients completed the
randomized treatment phases.
257 Multicenter, placebo-controlled,
randomized trial (July 2013 to final follow-up October 2
258 include in a sequential multiple-assignment
randomized trial (or randomized controlled trial) may be
259 Within a
randomized trial designed to examine nonspecific effects
260 This prospective,
randomized trial found that treat and extend dosing of r
261 This was a multicenter prospective
randomized trial including 143 patients with moderate-se
262 A
randomized trial is needed.
263 We conducted the first
randomized trial of behavioral weight loss for HIV-infec
264 FOURIER was a
randomized trial of evolocumab versus placebo in 27 564
265 In a phase 2B
randomized trial of patients with moderate to severe DG,
266 To our knowledge, this was the first
randomized trial to evaluate addition of an oncolytic vi
267 A prospective, international 1:1
randomized trial was conducted to evaluate in a noninfer
268 This
randomized trial was done to assess effectiveness of PRF
269 This multicenter
randomized trial with 2 parallel arms (drain vs no drain
270 mally invasive esophagectomy, a multicenter,
randomized trial).
271 METHODS AND In this cluster-
randomized trial, 10 primary health facilities in the ci
272 One
randomized trial, 3 quasi-experimental studies, and 40 o
273 Program (RAISE-ETP) study, a 34-site cluster-
randomized trial, compared NAVIGATE, a coordinated speci
274 In a recently published
randomized trial, compared with intensified treatment of
275 nemic.In this 2 x 2 factorial, double-blind,
randomized trial, nonpregnant women (aged 18-45 y) with
276 In this
randomized trial, off-pump CABG led to lower rates of 5-
277 In this
randomized trial, the routine use of pasireotide signifi
278 h neurocognitive effects in a recent phase 3
randomized trial.
279 =0.75 g/dl over any 4-week period during the
randomized trial; 57 [48.7%] versus 17 [14.8%] with plac
280 the era of drug-eluting stents, large-scale
randomized trials and all-comer registries have shown ex
281 More convincing data from
randomized trials are required to inform the management
282 Randomized trials evaluating treatment levels significan
283 Randomized trials have demonstrated increased morbidity
284 In 2
randomized trials in Guinea-Bissau of early BCG-Denmark
285 were combined for borderline personality and
randomized trials in PubMed, PsycINFO, EMBASE, and the C
286 ata meta-analysis of three large prospective
randomized trials in which sorafenib was the control arm
287 of studies of de-escalation of BMAs, and two
randomized trials of BMAs in control of pain secondary t
288 Recent meta-analyses and
randomized trials on secondary prevention of squamous ce
289 METHODS AND
Randomized trials reporting clinical outcomes beyond 1 y
290 Randomized trials support the use of transcatheter aorti
291 English-language cohort studies and
randomized trials that compared different doses of nalox
292 Randomized trials that reported pain, function, or harms
293 These findings support conducting
randomized trials to explore risks and benefits of OAT r
294 ous double-blind, placebo-controlled cluster-
randomized trials were revisited at age 8 y between Febr
295 Randomized trials with >/=50 patients, that had exclusiv
296 Constitutive Shisa2 expression causes
randomized turning of post-crossing commissural axons al
297 One hundred patients were
randomized with 96 completing the study (150 mL/min, n =
298 open-label period and a 26-week double-blind
randomized withdrawal period.
299 , phase 3, double-blind, placebo-controlled,
randomized withdrawal study including 418 participants w
300 We conducted a phase 3,
randomized withdrawal, multicenter, placebo-controlled,